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DISCUSSION: The majority of people that were treated
with statins stayed on these drugs although they used less
than was prescribed to them. Adherence to statins in-
creased over the years, however patients became less adher-
ent the longer they used them.
PCV11
STUDY OF HEALTH CARE RESOURCE USE FOR 
ELDERLY PATIENTS WITH MILD AND 
MODERATE ARTERIAL HYPERTENSION
Geltzer B, Frisman M
Vladivostok State Medical University, Vladivostok, Russia
OBJECTIVES: To study health care expenditures for pa-
tients with arterial hypertension.
METHODS: We observed elderly patients (n  186; mid-
dle age 68,4  2,2 years) from January 1997 to May 1999.
We investigated four medicines from the basic groups of
hypotensive drugs: nifedipine-GITS; enalapril; diltiazem;
indapamide. We defined duration of hospital treatment,
number of ambulant visits and emergency care.
RESULTS: Before treatment the middle number of ambu-
lant visits was 6,01 per year. Against a background of
monotherapy the number of visits was decreased: in nife-
dipine-GITS group (NG)—to 2,75 (CI 1,2–2,4); in enala-
pril group (EG)—to 3,27 (CI 1,5–3,1); in diltiazem group
(DG)—to 3,76 (CI 1,4–2,3); in indapamide group (IG)—to
5,28 (CI 1,4–3,2). Expenditures of health care were dimin-
ished: in NG—by 54,53%; in EG—by 46,14%; in DG—by
37,82%; in IG—by 12,69%. Before the treatment the mid-
dle duration of hospital treatment was 22,84 days. Against
a background of monotherapy the duration of hospital
treatment was decreased: in NG—to 14,25 days (CI 1,74–
3,48); in EG—to 16,63 days (CI 1,35–3,21); in DG—to
15,76 days (CI 1,42–3,38); in IG—to 16,57 days (CI 1,41–
3,23). Expenditures of health care were diminished: in
NG—by 37,62%; in EG—by 27,2%; in DG—by 31,01%;
in IG—by 27,47%. Combined economy in NG was
48,2%; in EG—27,76%; in DG—36,61%; in IG—32,3%.
RESULTS: This investigation provides comparative evalu-
ation of economy of health care resource with different
medicines.
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OBJECTIVES: To evaluate which ACE inhibitor, of the
10 that are marketed in Spain, offers the most favorable
cost-effectiveness relationship in the treatment of light-
moderate arterial HBP.
MATERIAL AND METHODS: Only direct costs derived
from treatment were taken into consideration. We have
calculated the cost of treatment per day (CTD) in the fol-
lowing way: By grouping the different pharmaceutical
products marketed in Spain by active ingredients. The price
of the daily defined dose (DDD) was established for each
product by dividing its price by the number of tablets that
the DDD requires in accordance with the recommended
dose in the information leaflet.
RESULTS: In more or less objective terms it is accepted
that therapeutic efficiency within the group of ACE inhibi-
tors is very similar and so efficiency depends exclusively on
the cost of the product. This has lead to the carrying out of
an analysis of the minimization of costs, and this shows
that the alternative with the lowest cost per controlled pa-
tient is Enalapril, so substituting this option for the rest of
ACE inhibitor prescriptions could result in very significant
savings. Potential savings could reach 10,801 Million Ptas.
per annum if the lower priced Enalapril were used.
CONCLUSIONS: Enalapril is the most cost-effective ACE
inhibitor for the treatment of light and moderate HBP in
Spain. Substituting Enalapril for prescriptions for the rest
of ACE inhibitors could lead to a significant saving poten-
tial in pharmaceutical spending. Changing to lower priced
Enalapril could increase the figure for potential savings by
up to almost 11,000 Million Ptas. per annum which makes
it the most efficient option.
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QUALITY-OF-LIFE-EVALUATION OF THE 
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Wendland G, Kurscheid T, Lauterbach KW
University of Cologne, Köln, Germany
OBJECTIVE: To assess the effectiveness of evidence-based
treatment of obesity in a primary care setting, we con-
ducted the S.A.T.-trial (Sibutramine in Adiposity Trial)
which is a multicenter, double-blind, placebo-controlled,
randomized parallel group comparison of 54-week contin-
uous therapy with Sibutramine 15 mg or Placebo in addi-
tion to a standardized non-pharmacological therapy con-
sisting of a calorie-restricted diet, modification of eating
behavior and lifestyle, and an activity programme. Patients
with a BMI between 30 and 40 are included. The primary
endpoint in this study is weight loss in kg between the last
measurement of body weight (visit 11) and the measure-
ment at the first visit. Secondary endpoints are amongst
other clinical parameters health economic and quality of
life data. Since the random code is still not broken, the re-
sults given in this abstract refer to all randomized obese
patients in the study (both Sibutramine and placebo
group). The presentation in November will show the re-
sults for the two patient groups separately.
QUALITY OF LIFE MEASURES: Quality of life is mea-
sured by 4 different instruments: the Short Form 36 (SF-36):
the EuroQol, the Time-trade-off-Method (TTO) and the
Willingness-to-pay-Method (WTP). The SF-36 is a general,
